As a cancer survivor, my heart goes out to you both. As someone who also works for a company that makes a checkpoint inhibitor, one of our chief efforts is to

As a cancer survivor, my heart goes out to you both. As someone who also works for a company that makes a checkpoint inhibitor, one of our chief efforts is to better understand what makes them work for some patients and not others. Not only would this knowledge serve the lucky patients by tuning their therapy for better efficacy and lesser side effects, but would help us know more about how CPIs fail, and ideally, to enable their use in the many, as yet, unlucky patients.